Neuroprotective Effect of Ginseng Total Saponins in Experimental Traumatic Brain Injury

INTRODUCTION

Ginseng, the root of *Panax ginseng* C.A. Meyer, is a well-known folk medicine and has been used as a tonic for over 2000 yr (1-3). Recently there has been a renewed interest in investigating ginseng-pharmacology using biochemical and molecular biology techniques (2).

Pharmacological effects of ginseng have been demonstrated in the central nervous, cardiovascular, endocrine, and immune systems (1-5). In addition, anti-neoplastic, anti-stress, and antioxidant activity have been ascribed to ginseng and its constituents (4, 5). Ginsenosides, which are a diverse group of steroidal saponins and triterpene derivatives containing sugar moieties, are the main active ingredients of ginseng with more than 30 ginsenosides isolated from the roots of *Panax ginseng* (1, 2).

Recognition that delayed biochemical reactions contribute substantially to tissue damage after head injury has led to the development of targeted neuroprotective strategies in order to limit such secondary posttraumatic cell death and to improve neurological recovery (6).

Previous reports demonstrated the neuroprotective effect of ginsenosides in vitro but rarely in vivo, especially in head trauma (1). In the present study, we evaluated whether treatment with ginseng total saponins (GTSs) can decrease hippocampal neuronal loss, cortical contusion volume, and neurological dysfunction following a controlled cortical impact (CCI) injury.

MATERIALS AND METHODS

Subjects

Twenty-four adult male Sprague-Dawley rats weighing 200-250 g were used for these experiments. All procedures were performed in accordance with the guidelines for care and use of laboratory animals approved by Chung-Ang University's Institutional Animal Care and Use Committee. Ginsenosides used in this study were GTSs obtained from the Korea Tobacco and Ginseng Research Institute (Daejon, Korea). One hundred grams of ginseng was boiled gently in 1,000 mL of water for 60 min. The extract was then concentrated under reduced pressure to obtain a residue.

Surgical procedures

The rats were anesthetized initially with ketamine hydrochloride (15 mg/kg, i.m.) and the head was fixed in a stereotaxic device (Small Animal stereotaxic instrument, David Kopf instrument, Tujunga, CA, U.S.A.), then maintained by 2% halothane mixed with oxygen and compressed air. After
292 Y.C. Ji, Y.B. Kim, S.W. Park, et al.

a 1.5 cm midline skin incision, a 5 mm diameter craniectomy was made over the right parietal cortex with an electric drill. The craniectomy was centered 3 mm lateral to the sagittal suture and 3 mm posterior to the bregma. Great care was taken to avoid damaging the underlying dura mater during the drilling and removal of the cranial bone.

Experimental controlled cortical injury

Traumatic brain injury (TBI) was performed using the CCI method as described previously (7). After the small craniectomy, an injury was produced using a CCI device (CAUH-2). The device consisted of a 4 mm metal impact tip that was pneumatically driven at a predetermined pneumatic pressure (70 psi), depth (3 mm), and duration of brain deformation (0.2 sec). The penetration depth of 3.0 mm was able to produce a moderate cortical impaction. The wound was closed with 3-0 silk sutures.

Administration of total saponins

The rats subjected to CCI injury were divided into three groups with six rats per group. Intra-peritoneal injections of GTSs or saline were performed immediately after injury (≤ 3 min post-injury). Rats in the 100 mg-GTSs, and 200 mg-GTSs-treated groups received GTSs dissolved in 1.0 mL saline at a dose of 100 and 200 mg/kg, respectively. Rats in the saline-treated group received 1.0 mL of saline. The sham-operated animals (n=6) received neither GTSs nor saline.

Neurological evaluation

Neurologic evaluation was performed after the TBI using the previously described method (8, 9). The neurobehavioral battery of tests consisted of a rotarod test using the Rota-Rod/7750 (Ugo Basile, Co., Comerio, Italy), beam-balance performance, and posture reflex test.

In the rotarod test, rats were placed on an accelerating rotarod. The time each rat remained on the rod was registered automatically. Neurologic deficit was estimated to be the time at which the rat could no longer remain on the rotarod at a speed of 40 rpm, up to 420 sec. If the rat remained on the rod longer, the test was completed and scored as 420 sec.

Vestibular function was evaluated based on beam-balance performance. Rats were placed on the beam with their head away from the wall, and allowed to remain for 60 sec. Each rat was given three trials, and a mean score was determined.

The posture reflex test evaluated movement asymmetry of the forelimbs as the rat was suspended by the base of the tail. Normal posture was determined to be the symmetrical reaching of both forelimbs toward the ground and was given a score of 3. Moderately abnormal posture, which was the flexion of the contralateral forelimb toward the body, was given score of 2. Severely impaired posture, characterized by flexion of the forelimb and rotation of the shoulder and/or body, was given a score of 1.

Neurological assessments were evaluated 24 hr before and after TBI by an investigator blinded to the study groups.

Extraction of the brain

After neurological evaluation, the rats were anesthetized again with halothane and the brains were removed from the calvarium and weighed. There was an identifiable focal cortical injury at the right parietal cortical area. The brain was cut into 2 mm-thick slices with a rat brain matrix (Harvard Bioscience Co., Holliston, MA, U.S.A.), and stained with 2% 2,3,5-triphenyl tetrazolium chloride (TTC, Sigma, Inc., St. Louis, MO, U.S.A.) at 37°C for 10 min. After staining, tissue slices were fixed with 4% buffered paraformaldehyde.

Contusion volume

The injury volume was calculated with a digital camera and an image analyzer program (OPTIMAS 6.3, Optimas, Inc., Bothell, WA, U.S.A.).

Histopathological study

The brain slices at the maximum injury site were made into paraffin-blocks. The prepared brain sections were cut into 5 μm-thick slices for hematoxylin and eosin (H-E) staining. Neuronal cells were counted in the hippocampal regions of CA1, CA2, and CA3 by a pathologist blinded to the study groups. For each rat, the mean number of neuronal cells was obtained by examining at least three serial coronal sections in the hippocampus underlying the area of contusion. In each section, neurons were counted in three non-overlapping fields under a high magnification (× 400) light microscope in each sub-region (CA1, CA2, and CA3). Only complete neuronal cells with a clearly defined cell body and nucleus were counted.

Apoptosis staining

TUNEL (TdT-mediated dUTP-biotin nick end-labeling) staining was performed using previously described methods (10), and was carried out using the TACS2 TDT-DAB kit (Trevigen, Inc, Gaithersburg, MD, U.S.A.). TUNEL stained cells were counted under a high magnification (× 400) light microscope.

Statistical methods

Neurological scores (Table 1), contusion volume (Table 2), and neuronal cell counts (Table 3) were presented as mean scores ± SD of the six rats per group. Data was compared between groups using one-way analysis of variance (ANOVA) followed by a Tukey-Kramer multiple-comparisons method.
P values of <0.05 were considered statistically significant.

RESULTS

Neurobehavioral assessment

24 hr after CCI injury, injured rats showed significant neurological deficits compared with the sham-operated rats. CCI injury led to definite impairments on all neurological function tests in saline-treated rats compared with the sham-operated rats (Table 1). The results of the rotarod test, beam balance performance test, and posture reflex test for saline-treated rats were $116.5 \pm 30.5\, \text{sec}$, $50.0 \pm 9.2\, \text{sec}$, and $1.8 \pm 0.4$, respectively (Table 1). In rats treated with GTSs (100 or 200 mg/kg) after the CCI injury, neurological deficits were improved significantly compared to saline-treated rats (Table 1). Rotarod test results for the 100 and 200 mg-GTSs-treated groups were 165.0 $\pm 43.7\, \text{sec}$, and $251.2 \pm 53.0\, \text{sec}$ respectively. The 200 mg-GTSs-treated rats showed a definite improvement in the rotarod test compared to saline-treated rats ($p<0.05$). Beam-balance performance and posture reflex test showed no significant difference between groups ($p>0.05$) (Table 1). Sham-operated rats did not show any neurological deficits.

Contusion volume

Contusion area was easily defined with 2% TTC staining in all injured rats (Fig. 1). Contusion volumes in the saline-treated group, 100 mg-GTSs, and 200 mg-GTSs-treated group were $32.5 \pm 3.5\, \mu\text{L}$, $26.5 \pm 2.9\, \mu\text{L}$, and $19.5 \pm 2.7\, \mu\text{L}$, respectively. Treatment with GTSs (100 or 200 mg/kg) significantly reduced the contusion volume by 18.5% in the 100 mg-GTSs-treated rats and 40% in the 200 mg-GTSs-treated rats relative to saline-treated rats (Table 2) ($p<0.05$). The effect of GTSs on contusion volume was increased in a dose-dependent fashion (Fig. 2). Sham-operated rats did not show any cortical lesion under 2% TTC staining.

Histopathological outcome

In the saline-treated rats, CCI injury caused significant neuronal loss after 24 hr in the CA2 (53.4%, $p<0.05$) and CA3 (54.6%, $p<0.05$) regions of the hippocampus (Fig. 3A-C) compared to the results from contralateral hippocampal

---

Table 1. Neurologic assessments after traumatic brain injury

|                | Rotarod (sec) | Beam-balance (sec) | Posture reflex score |
|----------------|---------------|--------------------|---------------------|
|                | Pre | Post | Pre | Post | Pre | Post |
| Saline-treated group | 420 | 116.5 $\pm$ 30.5 | 60 | 50.0 $\pm$ 9.2 | 3 | 1.8 $\pm$ 0.4 |
| 100 mg-GTSs-treated group | 420 | 165.0 $\pm$ 43.7 | 60 | 51.8 $\pm$ 7.8 | 3 | 2.0 $\pm$ 0.6 |
| 200 mg-GTSs-treated group | 420 | 251.2 $\pm$ 53.0 | 60 | 55.0 $\pm$ 5.6 | 3 | 2.3 $\pm$ 0.5 |

*All data are presented as the mean $\pm$ standard deviations. $^*$p<0.05. GTSs, ginseng total saponins; Pre, preoperative; Post, postoperative.

Table 2. Contusion volume after traumatic brain injury

|                | Contusion volume ($\mu\text{L}$) | Percentage of contusion volume (%)$^*$ |
|----------------|----------------------------------|--------------------------------------|
| Saline-treated group | 32.5 $\pm$ 3.5 | 100 |
| 100 mg-GTSs group | 26.5 $\pm$ 2.9 $^*$ | 81.5 |
| 200 mg-GTSs group | 19.5 $\pm$ 2.7 $^*$ | 60 |

*percentage of relative volume compared with mean contusion volume of saline-treated group. $^*$p<0.05, compared with saline-treated group.

$^*$p<0.05, compared with 100 mg-GTSs-treated group.

GTSs, ginseng total saponins.

Table 3. Number of neuronal cells in hippocampus after TBI

|                | CA1 | CA2 | CA3 |
|----------------|-----|-----|-----|
|                | Ipsilateral | Contralateral | Ipsilateral | Contralateral | Ipsilateral | Contralateral |
| Saline-treated group | 50.3 $\pm$ 3.9 | 59.7 $\pm$ 5.2 | 33.8 $\pm$ 4.2 | 72.5 $\pm$ 6.6 | 43.5 $\pm$ 5.0 | 66.5 $\pm$ 6.1 |
| 100 mg-GTSs-treated group | 55.3 $\pm$ 3.7 | 62.5 $\pm$ 6.8 | 51.2 $\pm$ 2.9 $^*$ | 66.1 $\pm$ 6.4 | 49.2 $\pm$ 3.8 $^*$ | 64.8 $\pm$ 4.3 |
| 200 mg-GTSs-treated group | 57.3 $\pm$ 3.1 | 63.3 $\pm$ 5.5 | 55.8 $\pm$ 2.6 $^*$ | 66.5 $\pm$ 6.6 | 55.3 $\pm$ 1.5 $^*$ | 64.2 $\pm$ 4.5 |

* $p<0.05$, compared with saline-treated group. $^*$ $p<0.05$, compared with 100 mg-GTSs-treated group. CA, cornu ammonis; GTSs, ginseng total saponins.
region (Fig. 3B, D) (Table 3). Treating rats with GTSs at a dose of 100 mg/kg showed significant decrease of the TBI-induced neuronal loss in the CA2 (22.7%, \(p<0.05\)) and CA3 (24.1%, \(p<0.05\)) regions relative to contralateral lesions (Table 3). 200 mg/kg GTSs dosage also showed significant TBI-induced neuronal loss decrease in the CA2 (16.1%, \(p<0.05\)) and CA3 (13.9%, \(p<0.05\)) regions (Fig. 3E, G) (Table 3). The protective effect of GTSs on hippocampal cell death was increased in a dose-dependent fashion (Table 3). There was no significant difference between groups in the CA1 region (Table 3) (\(p>0.05\)).

**TUNEL staining**

TUNEL-positive cells were found in the pericontusional zone in all injured groups. TUNEL-positive cells were not found in the contralateral cortex or in the contralateral hippocampal area. The number of TUNEL-positive cells was 11.5 ± 1.9 cells/HPF in the saline-treated rats, 10.8 ± 1.5 cells/HPF in the 100 mg-GTSs-treated rats, and 10.3 ± 1.8 cells/HPF in the 200 mg-GTSs-treated rats. There was no significant difference in the number of TUNEL-positive cells between groups (\(p>0.05\)). There were no TUNEL-positive cells in the sham-operated group.

**DISCUSSION**

In general, TBI mechanisms include changes in ionic homeostasis (such as calcium, potassium, sodium, and magnesium), release of excitatory amino acids, induction of free radicals, inflammatory/immune changes, and alterations of multiple neurotransmitter systems (11). It is also known that TBI leads
Neuroprotective Effect of GTSs

Ginsenosides may possess the ability to protect neurons from ischemic damage, and were shown to rescue hippocampal neurons from lethal ischemic damage possibly by scavenging free radicals, which are overproduced in situ after brain ischemia and reperfusion (19, 20). Another study described that the antioxidant action of ginsenosides was based on the chemical structure of ginsenoside Rb, similar to that of 21-aminosteroids (19). It also binds to glucocorticoid receptor with specific affinity and triggers transcriptional activation of glucocorticoid response elements-containing receptor plasmids (21). It promotes cell proliferation and enhances the survival rate of new-born cells (20).

We could not find a difference in the number of TUNEL-positive cells between groups. Previous studies describe that ginsenosides induce (22) or inhibit apoptotic cell death (23). Further studies are needed to evaluate the effect of ginsenosides on apoptosis relating to the TBI.

This study suggests for the first time that ginsenosides show a neuroprotective effect after experimental traumatic brain injury. However, because this study reflected effects of GTSs at 24 hr after traumatic brain injury, we could not define the time of maximal effect and duration of action. Further studies are needed to evaluate the effects of individual ginsenosides in TBI.

REFERENCES

1. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 1999; 58: 1685-93.
2. Kim S, Ahn K, Oh TH, Nah SY, Rhim H. Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochem Biophys Res Commun 2002; 296: 247-54.
3. Lee JH, Kim SR, Bae CS, Kim DH, Hong BN, Nah SY. Protective effect of ginsenosides, active ingredients of Panax ginseng, on kainic acid-induced neurotoxicity in rat hippocampus. Neurosci Lett 2002; 325: 129-33.
4. Kim HE, Oh JH, Lee SK, Oh YJ. Ginsenoside RH-2 induces apoptotic cell death in rat C6 glioma via a reactive oxygen- and caspase-dependent but Bcl-X(L)-independent pathway. Life Sci 1999; 65: 33-40.
5. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci 2001; 16 (Suppl): S28-37.
6. Faden AI. Neuroprotection and traumatic brain injury: the search continues. Arch Neurol 2001; 58: 1533-5.
7. Choi SM, Suk JS, Kwon JT, Min BK, Kim YB, Hwang SN, Choi DY, Kim JH, Lee SM, Earmme YY. Development of upgraded cortical impact model (Part I: Mechanics). J Korean Neurosurg Soc 2002; 32: 29-34.
8. Choi SM, Suk JS, Min BK, Hwang SN, Kim YB, Kim JH. Development of upgraded cortical impact model (Part II: Functional outcome). J Korean Neurosurg Soc 2002; 32: 458-62.
9. Wang LJ, Lu YY, Muramatsu S, Ikeuchi K, Fujimoto KI, Okada T, Mizukami H, Matsushita T, Hanazono Y, Kume A, Nagatsu T, Ozawa K, Nakano I. Neuroprotective effects of giall cell line-derived neurotrophic factor mediated by an adenov-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 2002; 22: 6920-8.
10. Wennersten A, Holmin S, Mathiesen T. Characterization of Bax and Bcl-2 in apoptosis after experimental traumatic brain injury in the rat. Acta Neuropathol (Berl) 2003; 105: 281-8.
11. Stelmasiak Z, Dudaowska-Konopa A, Rejdak K. Head trauma and neuroprotection. Med Sci Monit 2000; 6: 426-32.
12. Faden AI. Neuroprotection and traumatic brain injury: theoretical option or realistic proposition. Curr Opin Neurol 2002; 15: 707-12.
13. Lighthall JW. Controlled cortical impact: a new experimental brain injury model. J Neurotrauma 1988; 5: 1-15.
14. Lighthall JW, Dixon CE, Anderson TE. Experimental models of brain injury. J Neurotrauma 1989; 6: 83-97.
15. Goodman JC, Cherian L, Bryan RM Jr, Robertson CS. Lateral cortical impact injury in rats: pathologic effects of varying cortical compression and impact velocity. J Neurotrauma 1994; 11: 587-97.
16. Baskaya MK, Dogan A, Temiz C, Dempsey RJ. Application of 2,3,5-triphenyltetrazolium chloride staining to evaluate injury volume after controlled cortical impact brain injury: role of brain edema in evolution of injury volume. J Neurotrauma 2000; 17: 93-9.
17. Hamm RJ, Pike BR, O’Dell DM, Lyeth BG, Jenkins LW. The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 1994; 11: 187-96.
18. Liao B, Newmark H, Zhou R. Neuroprotective effects of Ginseng total saponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro. Exp Neurol 2002; 173: 224-34.
19. Lim JH, Wen TC, Matsuda S, Tanaka J, Maeda N, Peng H, Aburaya J, Ishihara K, Sakanaka M. Protection of ischemic hippocampal neurons by ginsenoside Rb1, a main ingredient of ginseng root. Neurosci Res 1997; 28: 191-200.
20. Shen L, Zhang J. Ginsenoside Rg1 increases ischemia-induced cell proliferation and survival in the dentate gyrus of adult gerbils. Neurosci Lett 2003; 344: 1-4.
21. Lee YJ, Chung E, Lee KY, Lee YH, Hur B, Lee SK. Ginsenoside-Rg1, one of the major active molecules from Panax ginseng, is a functional ligand of glucocorticoid receptor. Mol Cell Endocrinol 1997; 133: 135-40.
22. Chen XC, Chen Y, Zhu YG, Fang F, Chen LM. Protective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons. Acta Pharmacol Sin 2002; 23: 829-34.
23. Chen XC, Zhu YG, Zhu LA, Huang C, Chen Y, Chen LM, Fang F, Zhou YC, Zhao CH. Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. Eur J Pharmacol 2003; 473: 1-7.